Im­muno­Gen push­es read­out of rare blood can­cer tri­al to 2024

While Im­muno­Gen has an up­com­ing de­ci­sion date with the FDA for its lead ovar­i­an can­cer drug in No­vem­ber, the an­ti­body drug con­ju­gate-fo­cused biotech re­port­ed this morn­ing that the FDA pushed back on one of its oth­er pro­grams.

In its Q1 re­port, Im­muno­Gen had said that it would give a topline read­out from the CA­DEN­ZA study on pivekimab in blas­tic plas­ma­cy­toid den­drit­ic cell neo­plasm, or BPD­CN, a rare form of blood can­cer, pri­or to the end of the year. How­ev­er, af­ter meet­ing with the FDA, Im­muno­Gen said that it will be split­ting the study pa­tients in­to two groups — those for which BPD­CN is their first can­cer, and those who have had or cur­rent­ly have oth­er blood can­cers. (In more jar­gony terms, de no­vo pa­tients and pri­or or con­comi­tant hema­to­log­ic ma­lig­nan­cy (PCHM) pa­tients.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER